Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Growth Hormone
Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation.
Peptide B
Growth Hormone
The most potent GHRP — strong GH release with documented cardioprotective signaling.
Typical vial
2 mg
Typical dose
100-300 mcg
Half-life
~30 minutes (no DAC) / 6-8 days (with DAC)
FDA status
Not FDA approved for human use.
Typical vial
5 mg
Typical dose
100 mcg
Half-life
~55 minutes
FDA status
Not FDA approved for any indication.
CJC-1295 effects
Hexarelin effects
CJC-1295 side effects
Hexarelin side effects
CJC-1295 dosing ranges
Anti-aging and recovery (Mod GRF)
100 mcg · Once to three times daily (SubQ) · 8-12 weeks
Body composition (Mod GRF + Ipamorelin)
100-300 mcg · Two to three times daily · 8-12 weeks
CJC-1295 with DAC
1000-2000 mcg · Once or twice weekly · 8-12 weeks
Hexarelin dosing ranges
Short-course GH stimulation
100 mcg · Two to three times daily (SubQ) · 4 weeks maximum, then 4-week break
Combined with CJC-1295 (Mod GRF)
100 mcg of each · Two to three times daily · 4 weeks on / 4 weeks off
Cardioprotective research
1-2 mcg/kg · Per protocol (research-only) · Variable
CJC-1295: Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation. Typical dose 100-300 mcg. Hexarelin: The most potent GHRP — strong GH release with documented cardioprotective signaling. Typical dose 100 mcg. Both fall under the Growth Hormone category.
Stacking CJC-1295 with Hexarelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
CJC-1295 is typically dosed: Once to three times daily (SubQ) for Anti-aging and recovery (Mod GRF); Two to three times daily for Body composition (Mod GRF + Ipamorelin); Once or twice weekly for CJC-1295 with DAC. Hexarelin is typically dosed: Two to three times daily (SubQ) for Short-course GH stimulation; Two to three times daily for Combined with CJC-1295 (Mod GRF); Per protocol (research-only) for Cardioprotective research.
CJC-1295: Not FDA approved for human use. Hexarelin: Not FDA approved for any indication.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free